ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
COVID vaccines

China and U.S. share tech in ASEAN for vaccine diplomacy edge

Drugmakers test new COVID-19 shots in region with eye on local production

A healthcare worker in Jakarta holds up a vial of the Sinopharm vaccine. Chinese and U.S. companies are conducting clinical trials for new alternatives in Indonesia.   © Reuters

JAKARTA/HANOI -- Vaccine diplomacy by China and the U.S. has entered a new stage as their drugmakers transfer technology to players in Southeast Asia to kick-start local production.

The region has welcomed these efforts, since it provides a greater boost to the pharmaceutical industry there and creates more jobs than shipments of ready-for-use coronavirus jabs. Some companies have even begun testing vaccines in Southeast Asia that have yet to receive authorization in the countries in which they were produced.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more